Cyclosporine-induced autoimmunity and immune hyperreactivity

Area of Science:

• Immunology
• Pharmacology
• Autoimmunity Research

Background:

• Cyclosporine (CS) is a potent immunosuppressive drug.
• CS can paradoxically enhance DTH responses and autoimmune conditions.
• The timing of CS administration relative to immunization influences its effects.

Purpose of the Study:

• To investigate the mechanisms by which Cyclosporine (CS) enhances immune responses and induces autoimmunity.
• To explore the impact of CS on T cell priming and immune tolerance pathways.
• To describe the different forms of CS-induced autoimmunity.

Main Methods:

• Analysis of DTH responses and immune cell activity in relation to CS administration timing.
• Investigation of CS effects on T cell activation, lymphokine production (e.g., IL-2), and Th1/Th2 balance.
• Characterization of CS-induced autoimmunity in various animal models (rats, mice) and human transplant recipients.

Main Results:

• CS inhibits IL-2 production but may not prevent antigen-specific T cell priming, leading to accelerated responses upon CS withdrawal.
• CS can aggravate or induce autoimmune diseases like arthritis, EAE, thyroiditis, uveitis, and myocarditis.
• Three forms of CS-induced autoimmunity are described: syngeneic GVHD, systemic autoimmune disease in CBA/N mice, and organ-specific autoimmunity in neonatally treated mice.

Conclusions:

• CS affects immune tolerance at multiple levels, including thymic medullary involution, inhibition of intrathymic deletion of low-affinity T cell clones, suppression of suppressor T cells, and prevention of T cell clonal anergy.
• The induction of autoimmunity by CS likely results from the disruption of multiple redundant immune tolerance mechanisms.
• Understanding these mechanisms is crucial for managing CS therapy and preventing adverse autoimmune effects.